SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI.X is trending as community members express strong conviction and excitement, using the term "WAGMI" (We Are All Gonna Make It) to foster a sense of unity. Discussions revolve around the token's potential for significant growth, its strong community, and its role within the broader meme coin cycle, particularly on the Solana blockchain and Pump.fun platform. Some users are highlighting the token's branding and positive messaging, suggesting it could be the next breakout narrative in the meme coin space.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as chatter swirls around potential partnerships with both Apple and TSMC, fueling speculation about its foundry business. Bullish investors are hoping for further gains, while some debate whether the recent surge is justified given the company's underlying financials and competitive landscape. Many community members are attributing the hype to government support and investment.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to analyst upgrades and excitement around its AI cloud business potential, with the community discussing price targets and potential for significant growth.  JPM's downgrade is being viewed skeptically, while some traders are looking for a pullback after the stock's recent surge.  The broader AI narrative and IREN's expansion in that sector are also key discussion points.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions of market manipulation and recent price drops, with some community members expressing concern and frustration while others see it as a buying opportunity. There's also significant chatter around meme coins built on Solana, particularly $PUPU.X, $UPDOG.X, $SHITCOIN.X and $FIRECOIN.X, with some touting them as the next big thing.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

LLY is trending due to European Commission marketing authorization of Kisunla donanemab for early Alzheimer's, and discussions around potential tariffs impacting pharma companies. Community members are weighing in on the implications of these tariffs given LLY's U.S. manufacturing expansion and potential advantages over competitors, while also debating the efficacy of LLY's oral GLP-1 pill compared to Novo Nordisk's for diabetes and weight loss.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQQF is trending as investors discuss its Nasdaq uplisting and potential impact, especially given its focus on quantum-safe cybersecurity. Community members are weighing the potential for institutional investment and the company's positioning within the quantum computing sector, while also noting recent volatility and potential dilution concerns. Some are pointing to Eric Jackson's past endorsements and upcoming symposium events as potential catalysts.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK.X is trending as a meme coin on the Solana network, with community members highlighting its strong narrative around disrupting traditional retirement plans. The coin's community is particularly active, and some believe it has the potential for significant growth. Community members are also discussing its market cap and potential for early retirement.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as community members discuss its potential to be the next PEPE, with many highlighting its availability on Phantom Wallet. The coin is associated with the Solana network, and traders are pointing to bullish chart patterns and strong buying activity. Some users are monitoring whale activity via Phantom.

Pump.fun

$PUMP.X is trending as community members discuss its potential as a leading platform for meme coins and streaming, with some pointing to recent buybacks and creator rewards as bullish signals.  However, the inherent volatility and risk associated with meme coins are also being debated.  Discussions extend to the broader Solana ecosystem and the potential for new coins launched on Pump.fun.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as discussions revolve around a boosted price target from an analyst, potentially signaling further upward momentum, while others point to declining sales figures and expiring EV subsidies, suggesting a possible downturn. The community is actively debating Tesla's financial health, delivery reports, and Elon Musk's strategic moves amid evolving competition in the EV sector. Broader market factors and technical levels are also being closely watched for potential directional shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results 

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

Company News for Sep 3, 2025

Companies In The News Are: SIG, PEP, CYTK, AL.

Retail chatter around Cytokinetics surged late&nbsp;Monday&nbsp;as the company’s shares jumped 34% in Europe after new data from its MAPLE-HCM study were presented at the European Society of Cardiology Congress 2025 in Madrid.Cytokinetics’ shares closed at €39.8 on Monday in Europe, up €10, or 33.6% from the prior session.The company stated that its experimental drug, aficamten, improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy, whereas treatment with the current standard of care, metoprolol, reduced it.The primary results were also published in The New England Journal of Medicine.MAPLE-HCM is a Phase 3 randomized, double-blind, active-comparator trial that enrolled 175 patients, who were assigned one-to-one to receive either aficamten or metoprolol as monotherapy.&nbsp;Cytokinetics said the trial was designed differently from its pivotal SEQUOIA-HCM study, enrolling patients with less severe disease, including those without obstruction at rest and with higher predicted peak oxygen uptake.Fady I. Malik, executive vice president of research and development, said the clinical difference between the two treatments was reinforced by secondary endpoints on symptoms, functional class and left ventricular outflow tract (LVOT) gradients, and that the benefits were seen in a broader patient population than in SEQUOIA-HCM.Cytokinetics also presented additional data from MAPLE-HCM at the ESC Congress, including a pre-specified analysis of aficamten’s effect on cardiac structure and function, published in the Journal of the American College of Cardiology.&nbsp;A late-breaking clinical science presentation on the incidence and impact of atrial fibrillation associated with aficamten was simultaneously published in Heart Rhythm.“The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy,” Malik said.&nbsp;On Stocktwits, retail sentiment for Cytokinetics was ‘extremely bullish’ amid a 150% surge in 24-hour message volume.One user stated that Cytokinetics appeared to be a clear buyout candidate, citing its head-to-head superiority over the standard-of-care metoprolol.<stembedurl>https://stocktwits.com/lebranjames/message/627145099</stembedurl>Another user noted that while Cytokinetics had strong data, it would still require significant funding, partnerships, and guideline updates before its drug could replace beta blockers, although they expected the stock to trade higher next week.&nbsp;<stembedurl>https://stocktwits.com/John62/message/627141611</stembedurl><a href="https://stocktwits.com/symbol/CYTK">Cytokinetics’ stock</a> has declined 25% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cytokinetics’ stock (CYTK) has declined 25% so far in 2025. (Photo credit: Getty Images)

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough 

The company unveiled Phase 3 MAPLE-HCM results showing aficamten outperformed metoprolol in obstructive hypertrophic cardiomyopathy, with findings published across top medical journals.

Equity

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Beats Q4 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$47.83
Prev Close	$48.29
Open	$48.02
Dividend Yield	0.00%
50-Day Moving Average	$41.63
Beta	0.92
Avg. Volume	1.69M
PE Ratio	-9.34

52-Week High	$59.39
52-Week Low	$29.31
Market Capitalization	$5.72B
EPS (Annual)	-$5.26
Price to Book	-15.51
Revenue Per Employee	$37,096.39
Enterprise Value/EBITDA	N/A

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTK Cytokinetics Inc